This Phase 3 study is designed to evaluate the effectiveness and safety of an investigational asthma medication that combines two types of treatments: a fast-acting rescue medicine that works quickly during asthma symptoms and a long-acting medicine that helps reduce inflammation and swelling in the lungs over time. The investigational combination will be compared with three other study treatments: the fast-acting rescue medication alone (albuterol), the long-acting medication alone (a corticosteroid), and a placebo that looks like the study drug but contains no active ingredients. During the double-blind treatment period, participants will be randomly assigned, in equal numbers, to one of these four treatment groups. Neither participants nor study staff will know which treatment is assigned, helping to prevent bias. Participants will take two puffs of their assigned study treatment four times a day—early morning, midday, early evening, and at bedtime—as consistently as possible.